Yoshimura Akinobu
Fourth Dept. of Internal Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan.
Gan To Kagaku Ryoho. 2004 Mar;31(3):318-21.
Bronchioloalveolar carcinoma (BAC) is a histological subtype of adenocarcinoma of the lung, which is divided into 3 types: non-mucinous, mucinous and mixed type. BAC is histologically defined as "an adenocarcinoma with a pure bronchioloalveolar growth pattern and no evidence of stromal, vascular or pleural invasion." Tumors showing a solitary nodule are recognized by ground-glass opacity on chest CT. Because surgical treatment for these cases results in a good outcome, more non-invasive procedures of surgical intervention, a limited resection and video-assisted endothoracic operation, have been investigated. There is no effective therapy for patients with BAC presenting multiple nodules or tumors resembling lobar pneumonia. Recently, the effectiveness of molecular targeting therapy (gefitinib, erlotinib) for BAC is reported.
细支气管肺泡癌（BAC）是肺腺癌的一种组织学亚型，分为3种类型：非黏液型、黏液型和混合型。BAC在组织学上被定义为“具有纯细支气管肺泡生长模式且无基质、血管或胸膜侵犯证据的腺癌”。表现为孤立结节的肿瘤在胸部CT上表现为磨玻璃影。由于这些病例的手术治疗效果良好，因此人们对更多非侵入性手术干预方法、有限切除和电视辅助胸腔手术进行了研究。对于出现多个结节或类似大叶性肺炎的肿瘤的BAC患者，没有有效的治疗方法。最近，有报道称分子靶向治疗（吉非替尼、厄洛替尼）对BAC有效。
